毗邻
发表于 2025-3-30 08:37:53
Ulrich Krystek,Eberhard Zuric scientific community expects the evidence to be convincing—for example, several independent lines of analyses performed on a feature where the results can only be explained by a biological process. (2) Most bodies are difficult to explore in situ, just about the only way to achieve the above goal
Mri485
发表于 2025-3-30 15:34:17
Roland Bergerverse. How would we recognize life if we encounter it or its remnants on an extraterrestrial body? This is the critical question of biosignature research to which astrochemical studies can contribute. Our understanding of preserved fossils and contemporary terrestrial life serves as a guide in the s
陈腐的人
发表于 2025-3-30 18:21:23
http://reply.papertrans.cn/43/4229/422890/422890_53.png
nephritis
发表于 2025-3-31 00:10:34
http://reply.papertrans.cn/43/4229/422890/422890_54.png
我怕被刺穿
发表于 2025-3-31 01:17:43
Michael Mirowt dental filling materials such as glass-ionomer cements, compomers, composites, and adhesive systems. In these materials, the fillers react with acids during the setting process or they improve the mechanical properties by increasing physical resistance, thermal expansion coefficient and radiopacit
向外供接触
发表于 2025-3-31 06:41:22
W. F. Ebkeistration conditions.Analysis of these drugs’ marketing (dru.Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world.
Musket
发表于 2025-3-31 11:16:01
http://reply.papertrans.cn/43/4229/422890/422890_57.png
Feigned
发表于 2025-3-31 16:57:31
Ch. Schindlere passage of the Affordable Care Act (ACA) created an FDA approval pathway for biosimilars, but that is the tip of the iceberg as it pertains to how a biosimilar will actually get to the patient. As a general rule, legislation contains very little detail and requires much regulatory guidance by vari
桶去微染
发表于 2025-3-31 21:10:16
Ulrich Steger,Christopher Kummers had been proven, clinical efficacy and safety profiles established, with large markets and sales margins, making them attractive targets for many biopharmaceutical companies, both large and small. However, inherent properties of the molecules result in higher levels of risk in the eyes of regulato
小鹿
发表于 2025-4-1 00:21:02
Ulrich Krystek,Eberhard Zurogical products entered the EU in 2006 and the U.S. in 2015. Unlike small molecule generic drugs, which are chemically identical to their originator products, biosimilar products cannot be identical because of the nature of biological molecules. However, as more than a decade of experience in Europe